The global HIV vaccine enterprise
- PMID: 16052457
The global HIV vaccine enterprise
Abstract
AIDS, which twenty-five years ago no one even knew it existed, has become the most serious infectious disease worldwide. The development of an HIV vaccine is one of the most difficult challenges that modern biomedical science is confronting. To address this challenge, scientists may need to organize themselves in a more intense, targeted, and collaborative effort, such as the one proposed by the Global HIV/AIDS Vaccine Enterprise. The enterprise concept proposes to complement the creativity of individual investigators with a collaborative system that ensures a more effective use of human and financial resources to produce new scientific knowledge. It also implies that the scientific knowledge can be harnessed in a targeted way to develop practical solutions to urgent global health problems, including explicit product development activities. Different modalities of the enterprise concept are being explored for the development of drugs to treat tuberculosis and vaccines to prevent malaria.
Similar articles
-
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.PLoS Med. 2005 Feb;2(2):e25. doi: 10.1371/journal.pmed.0020025. Epub 2005 Jan 18. PLoS Med. 2005. PMID: 15740411 Free PMC article.
-
Expanding research capacity and accelerating AIDS vaccine development in Asia.Southeast Asian J Trop Med Public Health. 2008 Jul;39(4):766-84. Southeast Asian J Trop Med Public Health. 2008. PMID: 19058617
-
G-8 endorses new global HIV vaccine enterprise.Bull World Health Organ. 2004 Jul;82(7):557. Bull World Health Organ. 2004. PMID: 15500292 Free PMC article. No abstract available.
-
The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise.Curr Opin HIV AIDS. 2010 Sep;5(5):414-20. doi: 10.1097/COH.0b013e32833cfe32. Curr Opin HIV AIDS. 2010. PMID: 20978383 Free PMC article. Review.
-
A new era in HIV vaccine development.Expert Rev Anti Infect Ther. 2007 Apr;5(2):205-15. doi: 10.1586/14787210.5.2.205. Expert Rev Anti Infect Ther. 2007. PMID: 17402836 Review.
Cited by
-
A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs.AIDS Res Hum Retroviruses. 2012 Dec;28(12):1745-55. doi: 10.1089/AID.2012.0023. Epub 2012 Jul 3. AIDS Res Hum Retroviruses. 2012. PMID: 22587371 Free PMC article.
-
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Front Immunol. 2014 Nov 18;5:593. doi: 10.3389/fimmu.2014.00593. eCollection 2014. Front Immunol. 2014. PMID: 25477882 Free PMC article. Review.
-
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330. PLoS One. 2010. PMID: 21179404 Free PMC article.
-
A Robust PCR Protocol for HIV Drug Resistance Testing on Low-Level Viremia Samples.Biomed Res Int. 2017;2017:4979252. doi: 10.1155/2017/4979252. Epub 2017 Apr 3. Biomed Res Int. 2017. PMID: 28473986 Free PMC article.
-
Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates.Virology. 2009 Oct 10;393(1):56-67. doi: 10.1016/j.virol.2009.07.021. Epub 2009 Aug 19. Virology. 2009. PMID: 19695656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical